{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "21406510",
  "DateCompleted": {
    "Year": "2012",
    "Month": "01",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "11",
    "Day": "19"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2011",
        "Month": "03",
        "Day": "15"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1183/09031936.00186510"
    ],
    "Journal": {
      "ISSN": "1399-3003",
      "JournalIssue": {
        "Volume": "38",
        "Issue": "3",
        "PubDate": {
          "Year": "2011",
          "Month": "Sep"
        }
      },
      "Title": "The European respiratory journal",
      "ISOAbbreviation": "Eur Respir J"
    },
    "ArticleTitle": "Effect of different asthma treatments on risk of cold-related exacerbations.",
    "Pagination": {
      "StartPage": "584",
      "EndPage": "593",
      "MedlinePgn": "584-93"
    },
    "Abstract": {
      "AbstractText": [
        "Common colds often trigger asthma exacerbations. The present study compared cold-related severe exacerbations during budesonide/formoterol maintenance and reliever therapy, and different regimens of maintenance inhaled corticosteroids (ICS), with or without long-acting \u03b2(2)-agonists (LABA), and with as-needed short-acting \u03b2(2)-agonists (SABA) or LABA. Reported colds and severe exacerbations (defined by oral corticosteroid use and/or hospitalisation/emergency room visit) were assessed for 12,507 patients during 6-12 months of double-blind treatment. Exacerbations occurring \u226414 days after onset of reported colds were analysed by a Poisson model. The incidence of colds was similar across treatments. Asthma symptoms and reliever use increased during colds. Budesonide/formoterol maintenance and reliever therapy reduced severe cold-related exacerbations by 36% versus pooled comparators plus SABA (rate ratio (RR) 0.64; p=0.002), and for individual treatment comparisons, by 52% versus the same maintenance dose of ICS/LABA (RR 0.48; p<0.001); there were nonsignificant reductions versus higher maintenance doses of ICS or ICS/LABA (RR 0.83 and 0.72, respectively). As-needed LABA did not reduce cold-related exacerbations versus as-needed SABA (RR 0.96). Severe cold-related exacerbations were reduced by budesonide/formoterol maintenance and reliever therapy compared with ICS with or without LABA and with as-needed SABA. Subanalyses suggested the importance of the ICS component in reducing cold-related exacerbations. Future studies should document the cause of exacerbations, in order to allow identification of different treatment effects."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Woolcock Institute of Medical Research, Australia. hkr@med.usyd.edu.au"
          }
        ],
        "LastName": "Reddel",
        "ForeName": "H K",
        "Initials": "HK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Jenkins",
        "ForeName": "C",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Quirce",
        "ForeName": "S",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sears",
        "ForeName": "M R",
        "Initials": "MR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bateman",
        "ForeName": "E D",
        "Initials": "ED"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "O'Byrne",
        "ForeName": "P M",
        "Initials": "PM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Humbert",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Buhl",
        "ForeName": "R",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Harrison",
        "ForeName": "T",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Brusselle",
        "ForeName": "G G",
        "Initials": "GG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Thor\u00e9n",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sj\u00f6bring",
        "ForeName": "U",
        "Initials": "U"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Peterson",
        "ForeName": "S",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ostlund",
        "ForeName": "O",
        "Initials": "O"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Eriksson",
        "ForeName": "G S",
        "Initials": "GS"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Randomized Controlled Trial",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Eur Respir J",
    "NlmUniqueID": "8803460",
    "ISSNLinking": "0903-1936"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Adrenal Cortex Hormones"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Ethanolamines"
    },
    {
      "RegistryNumber": "51333-22-3",
      "NameOfSubstance": "Budesonide"
    },
    {
      "RegistryNumber": "W34SHF8J2K",
      "NameOfSubstance": "Formoterol Fumarate"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "Eur Respir J. 2012 May;39(5):1280"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Adrenal Cortex Hormones"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [
        "complications",
        "therapy"
      ],
      "DescriptorName": "Asthma"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Budesonide"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child, Preschool"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Ethanolamines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Formoterol Fumarate"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Poisson Distribution"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Respiratory Tract Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    }
  ]
}